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Introduction: Bone marrow transplantation (BMT) 
is a treatment option for hematological diseases and 
immunodeficiency. It is frequently used today. BMT 
predisposes patients to upper airway infections and its 
complications, such as rhinosinusitis (RS). Chemotherapy, 
radiotherapy, viral infections, antibiotic therapy, graft 
versus host disease (GVHD) are rhinosinusitis predisposing 
conditions. Aim: to investigate RS frequence in this 
population and its relationship to GVHD; to try and establish 
the best treatment for RS in these patients. Method: ENT 
evaluation of two groups. One group with 35 patients (gI) 
and another with 24 patients (gII), before and after BMT. 
They were treated with antibiotics, maxillary sinus punction 
or endoscopic sinusectomy. Results: none of them had RS 
before BMT. 42.8% from gI had RS and 34% had GVHD; in 
the gII, 58% had RS and 25% had GVHD. 49% from both 
groups had RS and 30.5% had GVHD. There was significantly 
more RS in chronic GVHD patients. Surgery was used to 
treat RS in chronic GVHD patients who underwent BMT. 
Conclusion: RS frequence was 49%; GVHD is a predisposing 
condition to RS; sinusectomy may be necessary to control 
RS in GVHD patients.
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INTRODUCTION
Bone marrow transplant (BMT) is used as a treat-
ment for blood malignant and non-malignant diseases, 
immunedeficiencies and solid tumors1. Despite enhance-
ments in the techniques and drugs used in current trans-
plants, the bone marrow transplanted patient is prone to 
multiple upper airway infections and their complications 
during the first two years after the transplant2,3. Immunesu-
pression, radiotherapy, chemotherapy, antibiotic therapy, 
graft versus host disease (GVHD) and viral infections are 
described as predisposing factors for these infections and 
complications2-5, although the exact predictive value is yet 
to be defined.
We know that acute and chronic rhinosinusitis are 
frequent in transplanted and immunesupressed patients, 
specially in allogenic BMT, which donors may be relatives 
or not1. Although with low incidence (1.7%), invasive fun-
gus rhinosinusitis is the most feared upper airway disease, 
because its outcome is usually fatal5-7. Notwithstanding, 
bacterial rhinosinusitis occur much more frequently and 
recur more often in these transplanted patients, making its 
treatment a real challenge. Delays in diagnosis and treat-
ment of these rhinosinusitis may cause a fatal complication 
or BMT failure.
Treatment for recurrent or chronic bacterial rhino-
sinusitis in BMT patients differs from that in immunecom-
petent patients, because a number of factors contribute to 
maintain nasosinusal mucosal alterations and immunity. 
Among these factors, as the ones mentioned above, chronic 
Graft Versus Host Disease (cGVHD) seems to play an 
important role. It is known that chronic GVHD occurs at 
about 3 months following BMT in approximately 30% of 
the patients, while their immunity reacts favorably. There 
is gastrointestinal and respiratory mucosal involvement, 
among other organs, through a T lymphocyte reaction 
against class II antigens of these mucosal cells, causing 
local inflammation. Chronic GVHD may be classified into 
limited or extensive forms, depending on the number of 
organs involved. The better the patient’s immunity, the 
greater is the mucosal inflammatory reaction. Therefore, 
patients who develop chronic GVHD are medicated with 
immunesupressants to control this reaction, and this main-
tains a borderline immunity. 
According to the North American and Latin Ameri-
can Rhinosinusitis consensus, acute rhinosinusitis should 
be treated with antibiotics; and the chronic with anti-
inflammatory, antihistamine, decongestant medications, 
or even endonasal surgeries depending on the disease 
maintenance factor. For BMT the treatment advocated is 
based on broad spectrum antibiotics due to Immunesu-
pression. However, one must consider local factors such 
as severe mucosal edema due to the inflammation caused 
by chronic GVHD. In these situations it is likely that the 
surgical approach would be beneficial. 
This paper aims at studying the frequence of 
rhinosinusitis after bone marrow transplant and to study 
the association between rhinosinusitis and chronic graft 
versus host disease, and also the need for surgery to treat 
rhinosinusitis in BMT patients. 
MATERIALS AND METHODS
This is a retrospective study, carried out between 
September of 2001 and June of 2003, at the Otolaryngology 
and Hematology Departments of the University Hospital 
– State University of Campinas. The Ethics Committee for 
Research of the School of Medical Sciences of the Medi-
cal School UNICAMP approved this research project and 
we obtained an informed consent from all the participant 
patients. 
59 patients with hematological diseases and BMT in-
dication were assessed. They were divided in two groups. 
Group I comprised 35 patients who were assessed and 
followed before and after BMT. Group II, with 24 patients, 
was assessed only after BMT. 
The assessment followed a pre-established protocol 
of otorhinolaryngological interview, physical exam (otos-
copy, rhinoscopy, oroscopy, neck palpation), nasosinusal 
CT scan (coronal cross section) and/or paranasal sinus X-
rays. Paranasal sinus CT scan was carried out in 30 patients 
from group I and only in 6 patients from group II. 
Rhinosinusitis diagnosis was based on the param-
eters described by the North American and Latin American 
Consensus on Rhinosinusitis, in other words, we inves-
tigated time of evolution, symptoms (fever, facial pain, 
cough, nasal congestion and purulent rhinorrhea), puru-
lent secretion in the meatus seen at nasal endoscopy and 
radiological alterations (paranasal sinus veiling). Paranasal 
sinuses CT scan was carried out in 21 of all the patients 
who were diagnosed with rhinosinusitis and paranasal 
sinuses X-ray was done in 8 patients. 
Treatment was based on antibiotics as defined by 
the Hospital Infections Control Committee – University 
Hospital UNICAMP. When the patient presented with re-
fractory, recurrent or chronic rhinosinusitis with intranasal 
and/or paranasal sinus anatomical alterations (maxillary 
cyst, septal deviation, bullous conchae, polyposis, tumor) 
this patient underwent maxillary sinus punction through 
the canine fossa under local anesthesia for sinusal rigid 
endoscopy, mucosal and maxillary sinus biopsy and secre-
tion harvesting with sterile catheter introduced through the 
punction ostium for bacterial culture purposes; or, surgical 
removal of the obstructive factor in the middle meatus 
(maxillary, ethmoidal or sphenoidal endoscopic sinusec-
tomy), under general anesthesia. Patients were with high 
risk of intense nasal bleeding, because of acute myeloid 
leukemia and total bone marrow aplasia. Patients who 
did not present nasosinusal disease were only followed. 
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In Group I, the assessment was repeated after BMT and 
the treatment was carried out according to the alterations 
presented at the moment. 
Data statistical analysis was carried out through 
averages, medians, Yales-corrected chi-squared and Fisher 
Test.
RESULTS
Group I, which was assessed before and after 
BMT, comprised 35 adult patients with average age of 35 
years. Bone marrow transplant for this group was mostly 
allogenic (88%). None of them had rhinosinusitis before 
BMT. After BMT, 15 patients (42.8%) had rhinosinusitis. In 
this group, 12 (34%) patients developed chronic GVHD. 
There was no statistical significance between GVHD and 
rhinosinusitis. Notwithstanding, we noticed that over half 
of the patients with chronic GVHD  had rhinosinusitis, 
while only a quarter of the patients without chronic GVHD 
presented with rhinosinusitis (Table 1).
Group II, assessed after BMT, comprised of 24 pa-
tients of the same age range as those in group I, the type 
of transplant most frequently done was also the allogenic. 
In this group, 14 patients (58%) had rhinosinusitis; and 
six (25%) had cGVHD. We saw that all the patients with 
GVHD developed rhinosinusitis, and there was statistical 
significance (Table 2).
Since both groups presented similar characteristics 
as to the frequence of GVHD, we repeated the analysis 
in the set of both groups. (Table 3). The frequence of 
rhinosinusitis, in the total of 59 patients, was of 49% (29 
patients). GVHD occurred in 18 patients (30.5%). Rhinosi-
nusitis in the patients with GVHD is more frequent. Over 
two-thirds of the patients with chronic GVHD had rhino-
sinusitis; on the other hand, less than half of the patients 
without cGVHD had rhinosinusitis. There was statistical 
significance between rhinosinusitis and cGVHD.
Antibiotics were used for treatment in all the cases; 
however, some patients underwent maxillary, ethmoid 
and/or sphenoid sinusectomy to better control their rhi-
nosinusitis. We can see that a little bit more than half of 
the patients with cGVHD who had rhinosinusitis needed 
endoscopic sinusectomy to control the disease, while only 
one third of the patients without cGVHD underwent such 
surgery. However, there was no statistical significance in 
relation to surgery indication and rhinosinusitis among the 
cGVHD with BMT patients (Table 4).
DISCUSSION
Rhinosinusitis in transplanted patients is inevitable 
due to multiple intrinsic predisposing factors of the trans-
plant process (whole body radiotherapy, conditioning, 
long term antibiotic treatment, neutropenia, graft versus 
host disease, chemotherapy). Besides the major alteration, 
which is immunedeficiency in these patients, Cordon-
nier et al. showed cilliary alterations in the nasal mucosa 
that may predispose these patients to bacterial recurrent 
Table 1. Relationship between rhinosinusitis (RS) and chronic graft versus host disease (cGVHD) for group I.
WITH cGVHD WITHOUT cGVHD   P
With RS 7(58%) 8(34%) Chi-squared 1,785929952 0,181422943
Without RS 5(41%) 15(65%) Corrected 0,953728865 0,32877197
Total 12 23 Fisher test 0,164479051  
Table 2. Relationship between rhinosinusitis (RS) and chronic graft versus host disease (cGVHD) for group II.
 WITH cGVHD WITHOUT cGVHD   P
With RS 6(100%) 8(44%) Chi-squared 5,714285714 0,016827411
Without RS 0 10(55%) Corrected 3,657142857 0,055829302
total 6 18 Fisher test 0,022311213  
Table 3. Relationship between rhinosinusitis (RS) and chronic graft versus host disease (cGVHD) in all patients.
WITH cGVHD WITHOUT cGVHD   P
With RS 13 16 Chi-squared 5,515800704 0,018845446
Without RS 5 25 Corrected 4,267474613 0,03884863
Total 18 41 Fisher test 0,018752318  
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Table 4. Relationship between drug therapy (antibiotics) and surgery (FESS) and cGVHD.
WITH cGVHD WITHOUT cGVHD   P
Antibiotics 6 (46%) 11 (69%) Chi-squared 1,50973322 0,219179923
surgery 7 (54%) 5 (31%) Corrected 2,584965356 0,107882796
Total 13 16 Fisher test 0,197969436  
rhinosinusitis. The likelihood of the patient developing 
rhinosinusitis in the first two years after BMT is estimated 
to be up to 36.9%, according to Savage et al., going against 
findings of 49% of frequence in this paper.
According to numerous authors8-12, otorhinolaryn-
gological physical exam alone is not enough to properly 
assess these transplanted patients. Nasal endoscopy and 
paranasal sinus CT scan before BMT are ideal and funda-
mental tests used for the precise and early diagnosis. This 
way it is possible to know precisely of anatomical nasal 
conditions, nasal mucosa situation and paranasal sinus 
ostia, and to find tumors in the posterior nasal region. 
After BMT, endoscopy is the best test for a precise follow 
up of these transplanted patients, because there is a need 
to differentiate secretion color, mucosal edema or early 
fungi manifestations (gray, yellow or dark mucosa) in the 
entire nasal cavity. In suspicious cases of bacterial or fungi 
rhinosinusitis after BMT, it is possible to repeat the CT scan 
in order to plan treatment and disease staging. 
The occurrence of chronic graft versus host disease 
(cGVHD) is estimated to be of 60% in the patients submit-
ted to allogenic transplants1,2,4. In this paper, the frequence 
found was low (30.5%). We know that the cGVHD pa-
tients may have limited or extensive lesions (liver, skin, 
lungs, eyes) through auto-reactive T lymphocytes from 
the donor against class II antigen molecules common to 
the receiver1. In the lungs, obliterating bronchiolitis is the 
typical manifestation2. We have no specific report about 
nasosinusal mucosa alterations caused by cGVHD, but 
rather of the oral cavity mucosa, where we find important 
edema and lymphocyte build up in the submucosa. There 
is also association of immunedeficiency both humoral 
and cellular, and the use of immunosuppressive drugs 
to avoid the progression of cGVHD itself2. Cordonnier 
was not able to relate nasal mucosa cilliary alterations to 
cGVHD development. 
It is very likely that the airways are the first infec-
tion site because of its easy contact and contamination 
through the environment, having seen that immunity is 
deficient. Notwithstanding, the other factors, including 
Graft Versus Host Disease, participate in the maintenance 
of inflammation in the upper airways and rhinosinusitis 
recurrence. Thus, this paper has shown the influence of 
cGVHD in rhinosinusitis. It may be that the cilliary altera-
tions caused by cGVHD would cause the need for surgery 
in order to broaden the facial sinuses ostia, thus enhanc-
ing aeration and reducing secretion retention within the 
paranasal sinuses. Although this paper has failed to show 
any significance between paranasal sinus surgery indica-
tion and rhinosinusitis in the cGVHD BMT patients, we 
have seen clinically that these patients did not have more 
rhinosinusitis recurrences in the 2 year follow up period. 
Therefore, at the University Hospital -UNICAMP we chose 
to do nasosinusal endoscopic surgery in cGVHD BMT pa-
tients who had recurrence of rhinosinusitis (> 2-3 episodes 
in the semester) or chronic rhinosinusitis, or therapy failure 
even if it happened in the first episode. 
CONCLUSION
Rhinosinusitis frequence in BMT patients was of 
49%.
The frequence of chronic Graft Versus Host Disease 
was of  30.5%.
Chronic Graft Versus Host Disease is a predisposing 
factor for rhinosinusitis.
Nasosinusal surgery may be necessary to control 
rhinosinusitis in patients with chronic Graft Versus Host 
Disease. 
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